News >

Immune-Stimulator Boosts Pembrolizumab in Melanoma Patients With "Cold" Tumors

Jason Harris
Published: Friday, Oct 20, 2017

Adding the immune stimulator ImmunoPulse IL-12 to pembrolizumab (Keytruda) produced promising activity among patients with melanoma identified as unlikely responders to anti–PD-1 therapies.

PISCES/KEYNOTE-695 is a global, multicenter phase IIb, open-label study of intratumoral plasma encoded IL-12 (tavokinogene telseplasmid) delivered by electroporation in combination with IV pembrolizumab in patients with stage III/IV melanoma who have progressed or are progressing on either pembrolizumab or nivolumab (Opdivo) treatment.
Algazi A, Tsai K, Bannavong D, et al. Clinical immune monitoring and biomarker data of pil-12 monotherapy compared to pil-12 with pembrolizumab in metastatic melanoma supports the rationale for combination therapy. Presented at: 9th World Congress of Melanoma; October 18-21, 2017; Brisbane, Australia. Abstract FC05-3.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Publication Bottom Border
Border Publication